Genetic Testing (PGT/PGD)

Genetic Testing Before Embryo Transfer: What PGT and PGD Involve

Preimplantation genetic testing — PGT, historically called PGD — is a laboratory analysis performed on a small number of cells removed from an embryo created through IVF, before that embryo is transferred to the uterus. Depending on why you are testing, it looks for a specific inherited gene change, counts chromosomes, or checks for structural chromosome rearrangements. It is used by people who carry a known genetic condition, who have experienced recurrent miscarriage or repeated unsuccessful transfers, or who want chromosome information before deciding which embryo to transfer first.

For many people pursuing IVF, the question is not simply whether pregnancy is possible. It is whether there is a way to reduce the chance of passing on a condition rooted in the family’s genetics, to lower the likelihood of miscarriage related to chromosome differences, or simply to make better-informed choices before an embryo transfer. These concerns often carry years of weight: family history, previous loss, unsuccessful treatment, difficult medical decisions. Genetics can feel abstract until it becomes personal; then every detail matters.

Be clear from the start about what PGT is not. It does not create a “perfect” embryo, and it cannot predict every aspect of a child’s future health. Its purpose is narrower and more honest: to provide clinically meaningful information that helps you and your reproductive medicine team decide which embryos may be appropriate to consider for transfer.

The decision to test can feel emotionally and ethically complex. You may worry about what the results will show, whether enough embryos will be available, how accurate the testing is, how physically demanding the IVF process will be, and whether testing is genuinely necessary in your circumstances. A careful consultation makes those questions more manageable. At Acibadem, reproductive endocrinologists, embryologists, genetic counsellors and — when your history calls for it — other specialists review each case in the context of medical history, family history, fertility assessment and personal priorities. Some families use PGT to avoid transmitting a serious single-gene condition. Others consider it after recurrent pregnancy loss, repeated IVF failure, advancing maternal age or a chromosome finding in one partner. The appropriate pathway is individual, and part of a good evaluation is establishing whether PGT is the right tool for you at all — or whether another approach would serve you better.

What Is Preimplantation Genetic Testing (PGT/PGD)?

Preimplantation genetic testing is a laboratory evaluation performed on a small sample of cells removed from an embryo created through in vitro fertilisation. Testing happens before an embryo is transferred to the uterus — the feature that distinguishes it from every form of prenatal testing, which examines a pregnancy that already exists. In most modern IVF programmes, embryos are cultured to the blastocyst stage, usually around five to seven days after fertilisation, when a few cells can be biopsied from the trophectoderm, the embryo’s outer layer. That outer layer is destined to form the placenta; the inner cell mass, which develops into the fetus, is not biopsied.

The sampled cells are analysed in a specialised genetics laboratory. The embryo is usually frozen while results are being processed, allowing transfer to take place later in a carefully prepared frozen embryo transfer cycle. This approach gives the laboratory and clinical team time to review the results thoroughly and discuss the findings with you before any decision about transfer is made.

PGT is an umbrella term that covers three distinct forms of testing:

• PGT-M — testing for monogenic, or single-gene, conditions, previously often described as PGD. It is used when there is a known or suspected risk of a specific inherited disorder in the family. Examples include cystic fibrosis, thalassaemia, spinal muscular atrophy, Huntington disease, fragile X syndrome and many other inherited conditions. Before an IVF cycle begins, the laboratory develops a testing strategy tailored to the family’s known genetic finding.
• PGT-A — testing for aneuploidy, meaning an abnormal number of chromosomes. Embryos with an extra or missing chromosome are a common reason embryos fail to implant, miscarry, or result in certain chromosome conditions. PGT-A may help prioritise embryos for transfer in selected patients, but it does not change an embryo’s genetic makeup and it cannot create additional embryos.
• PGT-SR — testing for structural rearrangements, used when one prospective parent carries a chromosome rearrangement such as a balanced translocation or inversion. The carrier may be entirely healthy, yet some of their embryos may inherit an unbalanced chromosome arrangement that affects implantation, miscarriage risk or fetal development.

What does genetics mean?

Genetics is the branch of biology that studies genes, DNA and heredity — how characteristics and conditions pass from parents to children. Every cell in your body carries essentially the same set of genetic instructions, written in DNA and packaged into chromosomes; human cells normally carry 46 chromosomes arranged in 23 pairs. A gene is a stretch of DNA that carries the instructions for a particular protein or function, and a change in a single gene can be enough to cause a serious inherited disorder. In reproductive medicine, genetics matters because an embryo inherits half of its chromosomes from each parent, and errors in that inheritance — a missing chromosome, an extra one, an unbalanced segment, or a single altered gene — can affect whether a pregnancy establishes, whether it continues, and whether the child is affected by an inherited condition.

What are three types of genetics?

Genetics as a science is traditionally divided into three broad fields: classical or transmission genetics, which studies how traits and conditions pass between generations; molecular genetics, which examines the structure and function of DNA itself; and population genetics, which looks at how gene variants are distributed across groups of people. PGT draws mainly on molecular genetics — reading DNA sequences and counting chromosome material — but transmission genetics shapes the counselling you receive, because inheritance patterns determine what risk each embryo actually carries. It is a useful coincidence that PGT itself also comes in three forms: PGT-M for single genes, PGT-A for chromosome number, and PGT-SR for chromosome structure. Understanding which of the three applies to your situation is the first real step in planning treatment.

Is PGT the same as a DNA test?

PGT is a highly specialised DNA test — one performed on embryo cells rather than on blood, saliva or a cheek swab, and interpreted for a very specific reproductive purpose. Most DNA testing that people encounter is quite different: consumer ancestry kits, paternity checks, or clinical panels ordered on an adult’s blood sample. Those tests answer questions about a person who already exists. PGT answers a narrower question about a five- or six-day-old embryo: does this embryo carry the specific gene change or chromosome difference we are looking for? The sample is tiny — a handful of cells — which is precisely why the laboratory work is technically demanding and why results are reported with defined categories and stated limitations rather than as absolute certainties.

That last point deserves emphasis. PGT provides information about the cells that were tested, but it is not identical to diagnostic genetic testing during pregnancy. A small possibility of technical limitation, mosaic findings, or discordance between the sampled trophectoderm cells and the rest of the embryo remains. For this reason, patients who become pregnant after PGT are usually advised to discuss confirmatory prenatal testing options — chorionic villus sampling or amniocentesis — with their obstetrician and genetic counsellor. PGT reduces uncertainty; it does not remove it.

Who May Need PGT, and How Is the Need Identified?

Unlike most medical treatments, PGT is rarely prompted by physical symptoms. You can be healthy, have regular menstrual cycles and feel entirely well while carrying a gene variant or chromosome rearrangement that has real implications for your embryos. The need for testing is most often identified through family history, prior reproductive history, genetic carrier screening, chromosome analysis, or testing performed after an affected pregnancy or child.

PGT is commonly considered after recurrent miscarriage, particularly when chromosome abnormalities have been identified in pregnancy tissue or when one partner is known to carry a chromosome rearrangement. It may also be discussed after repeated unsuccessful embryo transfers — though implantation failure has several possible causes, and PGT is not the right answer for every patient in that situation. An honest team will say so.

For prospective parents with a known inherited condition in the family, genetic counselling is the centre of the assessment. The counsellor reviews medical records, prior molecular test results, family pedigrees and the inheritance pattern of the condition. If the relevant genetic change has not yet been identified, additional testing may be needed before PGT-M can even be designed, and in some cases DNA samples from relatives help establish a reliable family-specific testing approach. This preparatory work is typically coordinated through a hospital’s medical genetics department, working alongside the fertility clinic.

A fertility evaluation is also necessary, because PGT requires IVF. This usually includes ovarian reserve testing, ultrasound assessment, semen analysis, infectious disease screening and a review of any previous fertility treatment. The team weighs age, expected egg yield, sperm factors, uterine health, prior embryo development and the time you have available. These details help you understand, before committing, how likely it is that an IVF cycle will produce embryos available for testing and transfer.

What are signs of poor genetics?

There are no reliable outward “signs of poor genetics” — the phrase describes a popular idea, not a clinical concept. A person’s appearance, fitness or general health does not reveal whether they carry a recessive gene variant or a balanced chromosome rearrangement; carriers of serious inherited conditions are very often completely healthy themselves. What clinicians look for instead is concrete evidence: a documented family history of an inherited disorder, recurrent miscarriage, a previous child or pregnancy with a confirmed genetic diagnosis, or abnormal results on carrier screening or chromosome analysis. If none of those apply, routine genetic anxiety is rarely a reason for PGT on its own — and if one of them does apply, formal genetic counselling is a far better guide than any assumption drawn from how a family looks or feels.

Conditions and Reproductive Situations PGT Can Address

What diseases can be detected through genetic testing?

In the embryo setting, genetic testing can detect three broad categories of problem: specific single-gene disorders when the family’s causative variant is already known (PGT-M); whole-chromosome differences such as an extra or missing chromosome (PGT-A); and unbalanced chromosome material inherited from a parent’s structural rearrangement (PGT-SR). PGT-M covers autosomal recessive disorders, where both partners may be carriers; autosomal dominant disorders, where one affected parent has a chance of passing on the variant; and X-linked disorders, which may affect male and female children differently depending on the condition. What PGT cannot do is scan an embryo for every possible disease — each test answers the defined question it was designed to answer, and nothing more.

What are 10 genetic diseases?

Ten well-known examples of inherited conditions for which PGT-M is frequently considered, where the familial variant is known and a reliable assay can be developed, include:

• Cystic fibrosis — an autosomal recessive condition affecting the lungs and digestive system
• Beta-thalassaemia — an inherited haemoglobin disorder
• Sickle cell disease — another haemoglobin disorder, also autosomal recessive
• Spinal muscular atrophy — a progressive neuromuscular condition
• Huntington disease — an autosomal dominant neurological condition with later onset
• Fragile X syndrome — an X-linked cause of intellectual disability
• Duchenne muscular dystrophy — an X-linked muscle-wasting disorder
• Haemophilia A — an X-linked bleeding disorder
• Marfan syndrome — an autosomal dominant connective tissue condition
• Phenylketonuria — an inherited metabolic disorder

The list extends far beyond these examples: many metabolic disorders, muscular dystrophies and inherited neurological conditions can be addressed, and hereditary cancer predisposition syndromes may be considered in carefully evaluated circumstances. Families affected by inherited heart rhythm or heart muscle conditions are often assessed jointly with a cardiogenetics service, and inherited eye disorders with an ophthalmic genetics team, so that the reproductive question is answered with the right specialist input. Whether PGT is appropriate always depends on the specific gene, the family’s confirmed result, the reliability of the assay, applicable medical and ethical considerations, and your own wishes.

PGT-SR is valuable for individuals with balanced reciprocal translocations, Robertsonian translocations, inversions or other structural chromosome findings. A person with a balanced rearrangement often has no health concerns themselves, because the overall amount of genetic material is balanced. Their embryos, however, may receive an unbalanced amount of genetic material, which can lead to failed implantation, miscarriage or an affected pregnancy. Testing identifies which embryos carry balanced or normal chromosome complements.

PGT-A is most commonly considered where the likelihood of aneuploid embryos may be higher — with increasing maternal age, or after certain patterns of pregnancy loss. It may also be discussed when several embryos are available and you wish to use chromosome information to guide transfer order. Its value varies genuinely from one person to the next. It should be treated as a tool for embryo selection, not a universal requirement for IVF and not a substitute for comprehensive fertility care.

Equally important are the limits. PGT does not test for every genetic condition, developmental difference, birth defect or future health concern. It cannot assess intelligence, personality or appearance, and it cannot meaningfully predict complex diseases influenced by many genes and by environment. A thorough genetic counselling discussion should establish exactly what a proposed test can and cannot identify before you commit to a cycle.

What if you already have results from Myriad, Invitae or another laboratory?

Reports from commercial genetics laboratories such as Myriad or Invitae are often the starting point for PGT-M planning, and they are genuinely useful — provided the original document is available. The PGT laboratory needs the exact variant nomenclature from the report to design a family-specific assay, and in some cases it will ask for a confirmatory sample from you, your partner or affected relatives to validate the test before an IVF cycle begins. If your carrier screening or diagnostic testing was done years ago, the report may still be usable, but the team may recommend re-analysis under current classification standards, because the interpretation of some variants changes as evidence accumulates. None of this is wasted time: a PGT-M cycle built on an unverified result is a cycle built on sand.

How PGT Is Performed: From Preparation to Embryo Transfer

How is genetic testing done?

For embryos, genetic testing is done in six broad steps: assessment and test design, ovarian stimulation, egg retrieval and fertilisation, embryo biopsy, laboratory analysis, and — after results — frozen embryo transfer. This differs fundamentally from genetic testing on adults, which usually needs nothing more than a blood or saliva sample; embryo testing requires a full IVF cycle, because the embryo must exist in the laboratory before it can be biopsied. The process begins well before egg collection. You first meet a reproductive medicine specialist to review your fertility history, genetic history and treatment goals. If PGT-M or PGT-SR is being considered, the genetics consultation and laboratory review are particularly important: the laboratory must confirm that a validated testing strategy can be established and specify which samples or prior results it needs. Developing a family-specific PGT-M assay can take additional time, so planning before an IVF cycle starts is often the difference between a smooth pathway and a frustrating one.

1. Genetic and fertility assessment

Before treatment starts, the team reviews relevant genetic reports and may recommend carrier screening, confirmatory molecular testing, chromosome analysis or further evaluation of a known family condition. Fertility tests guide medication selection and give a realistic estimate of your expected response to ovarian stimulation. The discussion should also cover a difficult possibility: that a cycle may produce no embryos, no testable embryos, or no embryos suitable for transfer. It is hard to sit with that beforehand, but understanding it supports genuinely informed decisions — and protects you from surprises that are much harder to absorb mid-cycle.

2. Ovarian stimulation and monitoring

During the IVF cycle itself, fertility medications stimulate the ovaries to mature multiple eggs rather than the single egg of a natural cycle. You attend monitoring visits — ultrasound examinations and blood tests — so the care team can adjust dosing and determine the optimal moment for egg retrieval. The exact medication plan is set by your treating doctor and varies with ovarian reserve, age, medical history, how your body responds, and any prior IVF outcomes.

3. Egg retrieval and fertilisation

Egg retrieval is generally performed under sedation or anaesthesia. Using ultrasound guidance, the physician collects eggs from the ovaries through the vagina. The procedure itself is typically brief, and most patients go home the same day with instructions for recovery.

Retrieved eggs are fertilised in the embryology laboratory. Intracytoplasmic sperm injection — ICSI — is frequently used in PGT cycles, because injecting a single sperm into each egg supports controlled fertilisation and reduces the possibility of DNA from sperm cells surrounding the egg contaminating the later biopsy sample. The resulting embryos are cultured in tightly controlled incubator conditions and observed as they develop over the following days.

4. Blastocyst culture and embryo biopsy

Embryos that reach the blastocyst stage may be suitable for biopsy. Embryologists use high-resolution microscopy and micromanipulation techniques to remove a small number of trophectoderm cells, with methods designed to preserve embryo viability. Two honest caveats belong here: not every fertilised egg develops into a blastocyst, and not every blastocyst is suitable for biopsy. This natural attrition is an ordinary part of IVF biology and should be part of your counselling from the start.

On biopsy day, the sequence in the laboratory typically runs as follows:

1. Each blastocyst is assessed and identified under the laboratory’s witnessing system.
2. A few trophectoderm cells are removed by micromanipulation.
3. The biopsied cells are placed in secure, individually labelled tubes for the genetics laboratory.
4. The embryo is vitrified — a rapid freezing process — to preserve it until results are available.

Controlled culture environments, digital witnessing systems and precise cryopreservation methods support accuracy, traceability and consistent handling throughout the laboratory pathway. These process details are not glamorous, but they are where reliability actually lives.

5. Genetic analysis and result review

The genetics laboratory analyses the biopsied cells using next-generation sequencing, targeted DNA analysis, chromosome copy-number assessment or other validated approaches, depending on the type of PGT required. Results may classify embryos as suitable for consideration under the stated testing objective, affected by the tested condition, carrying a familial variant, aneuploid, or inconclusive. In PGT-A, some results indicate mosaicism — the sampled cells show a mixture of chromosome patterns — and these require especially careful interpretation, because the reproductive potential of mosaic embryos varies.

Your physician and genetic counsellor then discuss the results with you in context: how many embryos fall into each category, what the findings mean, whether re-testing might be considered in limited circumstances, and how transfer priorities are determined. Good decisions here reflect clinical evidence, laboratory guidance and your own preferences together — never a laboratory label alone.

6. Frozen embryo transfer

When you are ready for transfer, the uterine lining is prepared in either a natural or medication-supported cycle, with ultrasound and, where appropriate, hormonal monitoring to determine timing. The transfer itself is usually a short outpatient procedure that does not require anaesthesia: a soft catheter is passed through the cervix under ultrasound guidance and one embryo is placed into the uterus. A pregnancy blood test generally follows about one to two weeks later, according to the clinic’s protocol.

From initial assessment through embryo transfer, the overall timeline ranges from several weeks to a few months. PGT-M preparation can extend this, especially when a custom assay must be developed and validated. The active egg retrieval portion is relatively short; the planning and result interpretation around it are what take time — and they are worth that time.

Why Timely Evaluation Can Matter

There is rarely a need to decide anything immediately, but early evaluation preserves options. Female age remains one of the strongest influences on egg and embryo chromosome status: as ovarian reserve and egg quality change over time, the number of embryos available for testing tends to fall. If you know you carry a genetic condition or a structural chromosome rearrangement, seeking counselling before trying to conceive — or early in fertility planning — keeps more paths open.

Delay carries its own costs. It may mean further pregnancies affected by a known condition, additional losses, or repeated cycles undertaken without a clear genetic strategy. Recurrent miscarriage is physically and emotionally exhausting, and repeated unsuccessful transfers add financial and psychological strain. PGT cannot prevent all loss or infertility — nothing can — but identifying an underlying genetic factor can make future care more targeted and future decisions less blind.

For hereditary conditions with later-onset symptoms, you may feel entirely well and may never have viewed reproductive planning as urgent. A genetic counselling appointment creates space to understand the inheritance pattern, weigh the reproductive choices available, and consider whether IVF with PGT aligns with your values. The goal throughout is informed choice, not pressure in either direction.

Potential Benefits of PGT

The value of PGT depends on the indication, the number and quality of embryos available, and your broader fertility profile. The benefits below describe what PGT may offer when it is clinically appropriate — note the careful verbs; they are deliberate.

Benefit	What It Means for You
More informed embryo selection	Testing provides genetic or chromosome information that helps the care team identify embryos to consider for transfer according to the agreed clinical objective.
Reduced likelihood of transmitting a known familial condition	For many single-gene conditions, PGT-M may help identify embryos not expected to be affected by the specific genetic change being tested.
Guidance after recurrent loss or chromosome findings	For selected patients, PGT-A or PGT-SR may clarify embryo chromosome status and support a more individualised transfer strategy.
Potentially fewer transfers to reach a viable pregnancy	When suitable embryos are available, genetic information may help prioritise transfer order. It cannot eliminate the possibility of implantation failure or miscarriage.
Time for deliberate decision-making	Because embryos are typically frozen after biopsy, you can review results with your physician and genetic counsellor before proceeding with transfer.
Reproductive planning for families with inherited risk	PGT is one option among several, allowing families to consider pregnancy using their own eggs and sperm while addressing a known genetic concern.

Recovery Timeline After IVF and PGT

Physical recovery relates mainly to ovarian stimulation and egg retrieval; the embryo biopsy happens in the laboratory and involves no procedure on your body at all. Emotional recovery — and the waiting period for results — can be every bit as significant, and it helps to plan for both.

Time Period	What to Expect
Day 1 after egg retrieval	Mild cramping, pelvic pressure, bloating, light spotting and tiredness are common. Most patients rest at home and avoid driving after sedation.
First week	Discomfort usually eases over several days while the laboratory continues embryo culture, biopsy where appropriate, and freezing. IVF teams also monitor for ovarian hyperstimulation syndrome, an uncommon response to stimulation medication that can involve worsening abdominal swelling, rapid weight gain, breathlessness or severe pain.
One to three weeks	Genetic results may become available, depending on the test type and laboratory pathway. A consultation is arranged to review findings and discuss next steps.
First month	Many patients begin preparation for a frozen embryo transfer, or plan a subsequent IVF cycle if needed. Timing depends on physical recovery, uterine preparation, results and personal readiness.
Longer term	Once pregnancy is established, routine obstetric care continues. Prenatal screening and diagnostic testing options should be reviewed with your obstetrician, because PGT does not replace prenatal assessment.

What Influences the Chances of a Good Outcome?

PGT is one element of a larger reproductive treatment plan, and its usefulness is shaped by the reason for testing and by factors that affect IVF more broadly. Maternal age, ovarian reserve, sperm quality, egg quality, embryo development, uterine health and the number of embryos available all matter. A technically accurate test cannot compensate for embryos that do not develop to the blastocyst stage, and a result indicating that an embryo is suitable for transfer cannot predict pregnancy with certainty. Anyone who tells you otherwise is selling, not informing.

For PGT-M, the clarity of the family’s genetic diagnosis and the quality of test development are central. The laboratory must be able to distinguish the relevant familial variant reliably and account for technical considerations such as allele dropout — the possibility that one gene copy escapes detection in a very small sample. For PGT-SR, the nature of the rearrangement and the laboratory’s ability to characterise the chromosome segments involved shape interpretation. For PGT-A, the number of embryos tested, maternal age and the possibility of mosaic results are the important variables.

Embryology laboratory quality plays a meaningful role too. Consistent culture conditions, skilled biopsy technique, rigorous sample identification, validated genetic workflows and transparent reporting all support reliable care. Equally important is the clinical judgment applied after results return: a specialist should interpret each report alongside embryo morphology, your reproductive history and current evidence, rather than treating a laboratory category as the sole basis for a decision.

You can support treatment by attending monitoring visits, following the medication plan your treating doctor prescribes, sharing complete medical information, and avoiding smoking and recreational drugs. But do not carry more responsibility than is yours to carry: many of the factors that determine embryo development are biological and outside any individual’s control.

What Does Genetic Testing Cost?

How much does genetic testing cost?

The cost of PGT is not a single figure — it is built from several components, and understanding them matters more than any headline number. The largest element is usually the IVF cycle itself, including fertility medication, monitoring, egg retrieval and laboratory culture; the genetic testing sits on top of that. Within the testing component, costs are driven by the type of PGT (PGT-M typically involves custom assay development and validation, which PGT-A does not), the number of embryos biopsied and analysed, whether family samples are needed for test design, embryo freezing and storage, and the later frozen embryo transfer cycle. Because each of these varies with your biology and your indication, a meaningful quote can only follow an individual assessment — an itemised written estimate, specifying exactly what is and is not included, is a reasonable thing to expect from any clinic.

Is genetic testing covered by insurance?

Coverage varies widely by country, insurer and policy, and often by indication. Some insurers and national health systems treat PGT-M for a documented serious inherited condition differently from PGT-A used for embryo selection, and IVF coverage itself is frequently subject to separate rules, caps or eligibility criteria. Before starting treatment, it is worth obtaining written confirmation from your insurer of what is covered, under which diagnosis codes, and whether pre-authorisation is required — verbal assurances have a way of evaporating when the invoice arrives.

How PGT Care Is Organised at Acibadem

PGT involves more than an IVF appointment; it requires a plan that coordinates genetic evaluation, laboratory preparation, treatment monitoring and follow-up in a medically sensible order. At Acibadem, reproductive medicine teams work within structured diagnostic pathways that bring together fertility specialists, clinical embryologists, genetic counsellors, medical genetics physicians and other specialists when a patient’s health history calls for broader input. Complex cases — a rare inherited condition, a chromosome rearrangement, recurrent pregnancy loss, cancer-related genetic risk or coexisting medical concerns — may be reviewed in multidisciplinary discussion so that the proposed test addresses the correct genetic question.

The structure of modern PGT also shapes how care is scheduled. Because embryos are frozen after biopsy, the retrieval phase and the transfer phase can be separated in time, which allows the genetics laboratory to complete its analysis without rushing and allows the transfer cycle to be timed around uterine preparation rather than laboratory deadlines. Prior genetic reports and existing medical records form the basis of test design, which is why the genetics laboratory reviews them before an IVF cycle is planned rather than after it has begun — an ordering of steps that prevents cycles from starting without a validated assay in place.

A well-run pathway also recognises that patients differ in how much information they want, what timelines are realistic, and how they weigh genetic findings against other considerations. The team’s job is to explain options clearly, state limitations plainly, and support decisions that are both medically sound and personally right for you.

Preparing for a Specialist Review

Whether or not PGT turns out to be right for you, a specialist review works best when it starts from complete information. The documents that make the biggest difference are prior genetic reports with exact variant details, chromosome analysis results for both partners, fertility investigations, records of previous IVF cycles including embryo development notes, pregnancy and loss history, and relevant family medical information. With these in hand, a reproductive specialist and genetic counsellor can assess whether PGT-M, PGT-A or PGT-SR is relevant to your circumstances, what preparation would be required, and — just as importantly — what the alternatives look like: natural conception with prenatal diagnostic testing, donor gametes, or proceeding without testing at all. Thoughtful planning cannot remove every uncertainty from reproduction. What it can do is replace assumptions with a clear-eyed understanding of your actual options, their realistic limits, and the order in which decisions need to be made.